Table 2 Epidemiological studies of whole cannabis and cannabis extracts for anxiety (part 2)
From: Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties
Study | Data Source | Number | Route of Administration | Outcome |
|---|---|---|---|---|
Cuttler et al. 2016 [59] | Recruited via word-of-mouth and links on advertisements posted on various websites and in Washington State cannabis dispensaries | 1418 participants | Inhaled- (joints, bong, pipe, vaporiser) – (M) 89.8%, (F) 88% Oral- (M) 3.9%, (F) 7.9% Concentrates- (M) 5.4%, (F) 3.1% Topical- (M & F) 0.4% Other- (M) 0.6%, (F) 0.73% | Male: 55.3% Female: 57.2% Reported feeling less anxious or fearful |
Corroon et al. 2017 [53] | Recruited via social media | 2774 participants | N/A | 46% reported using cannabis as a substitute for prescription drugs |
Piper et al. 2017 [54] | New England dispensary members | 1513 participants | N/A | 71.8% reduced medication prescribed for anxiety |
Corroon et al. 2018 [55] | Recruited via social media. | 2409 participants | N/A | Almost 62% of CBD users reported using CBD to treat a medical condition. The top three medical conditions were pain, anxiety, and depression |
Feingold et al. 2018 [58] | Data was drawn from Waves 1 and 2 of the National Epidemiologic survey on Alcohol and Related Conditions | 3723 participants | N/A | Remission rates for non-users: 66.0% Remission rates for users: 52.8%) |
Cuttler et al. 2018 [57] | Data from the cannabis tracking app StrainprintTM | 5085 tracking sessions | Inhalation (smoking, vaping, concentrates, dab bubbler, dab portable) | 93.5% of sessions recorded decrease in anxiety |